静脉注射和口服探针在肝脏和首过 CYP3A 活性方面的受试者间差异。

IF 4.6 2区 医学 Q1 PHARMACOLOGY & PHARMACY Clinical Pharmacokinetics Pub Date : 2024-08-01 Epub Date: 2024-07-29 DOI:10.1007/s40262-024-01406-y
Evan D Kharasch, Christine Hoffer, Pamela Bedynek
{"title":"静脉注射和口服探针在肝脏和首过 CYP3A 活性方面的受试者间差异。","authors":"Evan D Kharasch, Christine Hoffer, Pamela Bedynek","doi":"10.1007/s40262-024-01406-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Clearances and the area under the plasma concentration-time curve extrapolated to infinity (AUC<sub>0-∞</sub>) of intravenous (IV) and oral midazolam and alfentanil are probes for hepatic and first-pass cytochrome P450 3A (CYP3A) activity, drug interactions, and phenotyping. Single-time plasma concentrations are also used as a proxy for clearance and AUC<sub>0-∞</sub>. Pupil diameter change is a noninvasive surrogate for plasma alfentanil. An ideal probe should have minimal intrasubject (interday) variability. Despite their widespread use, the intrasubject variability of CYP3A probes is not well characterized. This investigation determined the intrasubject (interday) variability of midazolam and alfentanil metrics of hepatic and first-pass CYP3A.</p><p><strong>Methods: </strong>Twelve volunteers were studied in a four-period protocol, with each period identical and separated by approximately 2 weeks. In each period, participants received 1 mg IV midazolam then 15 μg/kg IV alfentanil 1 h later. The next day, they received 3 mg oral midazolam then 60 μg/kg oral alfentanil. Plasma drug concentrations were determined by liquid chromatography-mass spectrometry (LCMS). Dark-adapted pupil diameters were measured coincident with blood sampling. Plasma concentrations and pupil effects (miosis) were analyzed using noncompartmental methods. The results were the coefficient of variation (%CV, mean ± SD) across four sessions in 12 participants.</p><p><strong>Results: </strong>For IV midazolam: AUC<sub>0-∞</sub>, clearance, and 5 h concentration, the %CVs were 12 ± 3, 12 ± 3, and 18 ± 8. For IV alfentanil AUC<sub>0-∞</sub>, clearance, 2 h concentration, and area under the effect curve from time zero to infinity (AUEC<sub>0-∞</sub>), the %CVs were 16 ± 5, 15 ± 4, 22 ± 7, and 50 ± 28. For oral midazolam AUC<sub>0-∞</sub>, clearance, and 5 h concentration, %CVs were 19 ± 5, 18 ± 4, and 28 ± 11. For oral alfentanil: AUC<sub>0-∞</sub>, clearance, 4 h concentration, and AUEC<sub>0-∞</sub>, %CVs were 20 ± 4, 21 ± 4, 42 ± 26, and 37 ± 14.</p><p><strong>Conclusions: </strong>Midazolam and alfentanil had comparable intrasubject variabilities of clearance and AUC<sub>0-∞</sub>. Single-time point metrics had greater intrasubject variability than AUC<sub>0-∞</sub> and clearance. Miosis was a surrogate for alfentanil concentrations and provided real-time results, but intrasubject variability was greater than that of clearances and AUC<sub>0-∞</sub>.</p>","PeriodicalId":10405,"journal":{"name":"Clinical Pharmacokinetics","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity.\",\"authors\":\"Evan D Kharasch, Christine Hoffer, Pamela Bedynek\",\"doi\":\"10.1007/s40262-024-01406-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Clearances and the area under the plasma concentration-time curve extrapolated to infinity (AUC<sub>0-∞</sub>) of intravenous (IV) and oral midazolam and alfentanil are probes for hepatic and first-pass cytochrome P450 3A (CYP3A) activity, drug interactions, and phenotyping. Single-time plasma concentrations are also used as a proxy for clearance and AUC<sub>0-∞</sub>. Pupil diameter change is a noninvasive surrogate for plasma alfentanil. An ideal probe should have minimal intrasubject (interday) variability. Despite their widespread use, the intrasubject variability of CYP3A probes is not well characterized. This investigation determined the intrasubject (interday) variability of midazolam and alfentanil metrics of hepatic and first-pass CYP3A.</p><p><strong>Methods: </strong>Twelve volunteers were studied in a four-period protocol, with each period identical and separated by approximately 2 weeks. In each period, participants received 1 mg IV midazolam then 15 μg/kg IV alfentanil 1 h later. The next day, they received 3 mg oral midazolam then 60 μg/kg oral alfentanil. Plasma drug concentrations were determined by liquid chromatography-mass spectrometry (LCMS). Dark-adapted pupil diameters were measured coincident with blood sampling. Plasma concentrations and pupil effects (miosis) were analyzed using noncompartmental methods. The results were the coefficient of variation (%CV, mean ± SD) across four sessions in 12 participants.</p><p><strong>Results: </strong>For IV midazolam: AUC<sub>0-∞</sub>, clearance, and 5 h concentration, the %CVs were 12 ± 3, 12 ± 3, and 18 ± 8. For IV alfentanil AUC<sub>0-∞</sub>, clearance, 2 h concentration, and area under the effect curve from time zero to infinity (AUEC<sub>0-∞</sub>), the %CVs were 16 ± 5, 15 ± 4, 22 ± 7, and 50 ± 28. For oral midazolam AUC<sub>0-∞</sub>, clearance, and 5 h concentration, %CVs were 19 ± 5, 18 ± 4, and 28 ± 11. For oral alfentanil: AUC<sub>0-∞</sub>, clearance, 4 h concentration, and AUEC<sub>0-∞</sub>, %CVs were 20 ± 4, 21 ± 4, 42 ± 26, and 37 ± 14.</p><p><strong>Conclusions: </strong>Midazolam and alfentanil had comparable intrasubject variabilities of clearance and AUC<sub>0-∞</sub>. Single-time point metrics had greater intrasubject variability than AUC<sub>0-∞</sub> and clearance. Miosis was a surrogate for alfentanil concentrations and provided real-time results, but intrasubject variability was greater than that of clearances and AUC<sub>0-∞</sub>.</p>\",\"PeriodicalId\":10405,\"journal\":{\"name\":\"Clinical Pharmacokinetics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pharmacokinetics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40262-024-01406-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacokinetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40262-024-01406-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:静脉注射(IV)和口服咪达唑仑和阿芬太尼的清除率和外推至无穷大的血浆浓度-时间曲线下面积(AUC0-∞)是肝脏和首过细胞色素 P450 3A(CYP3A)活性、药物相互作用和表型分析的探针。单次血浆浓度也可作为清除率和 AUC0-∞ 的替代指标。瞳孔直径变化是血浆阿芬太尼的无创替代物。理想的探针应具有最小的受试者内(日间)变异性。尽管 CYP3A 探针被广泛使用,但其受试者内变异性还没有得到很好的描述。本研究确定了咪达唑仑和阿芬太尼肝脏和首过 CYP3A 指标的受试者内(日间)变异性:对 12 名志愿者进行了四期研究,每期相同,相隔约 2 周。在每个阶段,参与者先接受 1 毫克咪达唑仑静脉注射,1 小时后再接受 15 微克/千克阿芬太尼静脉注射。第二天,参与者口服 3 毫克咪达唑仑,然后口服 60 微克/千克阿芬太尼。血浆药物浓度由液相色谱-质谱法(LCMS)测定。在采血的同时测量暗适应瞳孔直径。血浆浓度和瞳孔效应(瞳孔缩小)采用非室分析法进行分析。结果为 12 名参与者在四个疗程中的变异系数(%CV,平均值 ± SD):结果:静脉注射咪达唑仑静脉注射阿芬太尼的AUC0-∞、清除率和5小时浓度的变异系数分别为12±3、12±3和18±8;静脉注射阿芬太尼的AUC0-∞、清除率、2小时浓度和从零时到无穷大的效应曲线下面积(AUEC0-∞)的变异系数分别为16±5、15±4、22±7和50±28。口服咪达唑仑的 AUC0-∞、清除率和 5 h 浓度的百分比变异系数分别为 19 ± 5、18 ± 4 和 28 ± 11:AUC0-∞、清除率、4 h 浓度和 AUEC0-∞、%CV 分别为 20 ± 4、21 ± 4、42 ± 26 和 37 ± 14.结论:咪达唑仑和阿芬太尼的清除率和 AUC0-∞ 的受试者内变异性相当。与 AUC0-∞ 和清除率相比,单时点指标的受试者内变异性更大。Miosis 是阿芬太尼浓度的替代物,可提供实时结果,但受试者内变异性大于清除率和 AUC0-∞。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity.

Background and objectives: Clearances and the area under the plasma concentration-time curve extrapolated to infinity (AUC0-∞) of intravenous (IV) and oral midazolam and alfentanil are probes for hepatic and first-pass cytochrome P450 3A (CYP3A) activity, drug interactions, and phenotyping. Single-time plasma concentrations are also used as a proxy for clearance and AUC0-∞. Pupil diameter change is a noninvasive surrogate for plasma alfentanil. An ideal probe should have minimal intrasubject (interday) variability. Despite their widespread use, the intrasubject variability of CYP3A probes is not well characterized. This investigation determined the intrasubject (interday) variability of midazolam and alfentanil metrics of hepatic and first-pass CYP3A.

Methods: Twelve volunteers were studied in a four-period protocol, with each period identical and separated by approximately 2 weeks. In each period, participants received 1 mg IV midazolam then 15 μg/kg IV alfentanil 1 h later. The next day, they received 3 mg oral midazolam then 60 μg/kg oral alfentanil. Plasma drug concentrations were determined by liquid chromatography-mass spectrometry (LCMS). Dark-adapted pupil diameters were measured coincident with blood sampling. Plasma concentrations and pupil effects (miosis) were analyzed using noncompartmental methods. The results were the coefficient of variation (%CV, mean ± SD) across four sessions in 12 participants.

Results: For IV midazolam: AUC0-∞, clearance, and 5 h concentration, the %CVs were 12 ± 3, 12 ± 3, and 18 ± 8. For IV alfentanil AUC0-∞, clearance, 2 h concentration, and area under the effect curve from time zero to infinity (AUEC0-∞), the %CVs were 16 ± 5, 15 ± 4, 22 ± 7, and 50 ± 28. For oral midazolam AUC0-∞, clearance, and 5 h concentration, %CVs were 19 ± 5, 18 ± 4, and 28 ± 11. For oral alfentanil: AUC0-∞, clearance, 4 h concentration, and AUEC0-∞, %CVs were 20 ± 4, 21 ± 4, 42 ± 26, and 37 ± 14.

Conclusions: Midazolam and alfentanil had comparable intrasubject variabilities of clearance and AUC0-∞. Single-time point metrics had greater intrasubject variability than AUC0-∞ and clearance. Miosis was a surrogate for alfentanil concentrations and provided real-time results, but intrasubject variability was greater than that of clearances and AUC0-∞.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.80
自引率
4.40%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics. Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
期刊最新文献
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug–Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1